{
  "id": "5e81d6c6835f4e4777000030",
  "type": "summary",
  "question": "What is known about EphA2 in drug resistance?",
  "ideal_answer": "ligand- and tyrosine kinase-independent EphA2 signaling (the noncanonical pathway) promotes tumor survival and metastasis and controls acquired drug resistance and maintenance of cancer stem cell-like properties.\nFindings confirm EPHA2 as an actionable drug target, provide a rational basis for drug combination approaches, and indicate that chemical proteomics is broadly applicable for the discovery of kinase inhibitor resistance.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30055288",
    "http://www.ncbi.nlm.nih.gov/pubmed/28966234",
    "http://www.ncbi.nlm.nih.gov/pubmed/29048432",
    "http://www.ncbi.nlm.nih.gov/pubmed/25963923",
    "http://www.ncbi.nlm.nih.gov/pubmed/26744526"
  ],
  "snippets": [
    {
      "text": "Existing research points to the potential use of various Eph/ephrin members as biomarkers for assessing prognosis and selecting the most suitable therapeutic strategies in variable clinical scenarios, also for overcoming drug resistance, in the era of breast cancer heterogeneity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30055288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "increased levels of the previously reported resistance mediators, receptor tyrosine kinase ephrine receptor A2 (EPHA2) and the hepatocyte growth factor receptor MET were also identified",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ligand- and tyrosine kinase-independent EphA2 signaling (the noncanonical pathway) promotes tumor survival and metastasis and controls acquired drug resistance and maintenance of cancer stem cell-like properties.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28966234",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744526",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963923",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These findings confirm EPHA2 as an actionable drug target, provide a rational basis for drug combination approaches, and indicate that chemical proteomics is broadly applicable for the discovery of kinase inhibitor resistance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25963923",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}